Kornimate/medical-research-clean huggingface dataset:
a clinical study of anfibatide in acquired thrombotic thrombocytopenic purpura (ttp)

Conditions: Acquired Thrombotic Thrombocytopenic Purpura

Summary: this is a multicenter, randomized, double-blind, parallel, placebo-controlled phase ii clinical study. it is planned to recruit 74 patients with acquired thrombotic thrombocytopenic purpura (ttp). to evaluate the efficacy and safety of anfibatide as an adjuvant therapy for plasma exchange in patients with acquired ttp.

the study will consist of 3 periods: screening(up to 7 days), treatment and follow-up(up to 3 months). subjects are assigned in a 1:1 ratio to anfibatide or placebo during plasma exchange with the use of a computerized randomization schedule. the administration is 5 iu/60kg intravenous infusion and 0.002 iu/kg/h continuous intravenous infusion. plasma exchange as the main treatment method is performed daily on the 5th day of solstice and then adjusted to every other day. fresh frozen plasma（ffp）and cryoprecipitate-reduced plasma are preferred. subjects will receive the study drug immediately after daily plasma exchange.

Eligibility criteria:
inclusion criteria: 1. female and male subjects with 18 years of age or older. 2. subjects with diagnosis of ttp. 3. necessitating plasma exchange. 4. obtained, signed and dated informed consent. exclusion criteria: 1. platelet count greater or equal to 100\*10\^9/μl. 2. severe heart, liver and kidney dysfunction, including those with glutamic-pyruvic transaminase ≥ 5xuln，glomerular filtration rate \<30ml/min. 3. uncontrolled severe active infection. 4. known congenital ttp. 5. subjects with malignant tumors in the past 5 years. 6. other diseases that cause microangiopathy hemolytic anemia and thrombocytopenia, such as disseminated intravascular coagulation (dic), antiphospholipid antibody syndrome, hemolytic uremic syndrome, malignant hypertension, and transplant-related microangiopathy. 7. pregnant or lactating women. subjects of reproductive age, are unable to use effective contraceptive methods during the study period. 8. severe active bleeding or progressive aggravation of bleeding symptoms. 9. subjects who have received plasmapheresis during the treatment of the onset of the disease. 10. subject is participating in other clinical stuy or is less than 3 months away from the end of previous clinical study. 11. subject who have participated in other clinical trials related to anfibatide. 12. severe or life threatening clinical condition other than ttp that would impair participation in the trial. 13. life expectation less than 1 week. 14. known to be allergic to the drugs or ingredients in the study. 15. inability to follow programme requirements and procedures. 16. subjects who are not eligible to participate in this clinical study as determined by the investigator.
collection of electrophysiological data during colon resection

Conditions: Open/ Laparoscopic/ Robotic Resection of the Colon

Summary: the study is conducted to record continuous electrophysiological signals from intact and ischemic bowel tissue during colonic resection surgery, in order to train the exero medical leak detection system classification algorithm on detection of ischemic conditions.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. patient is scheduled for open colonic resection, (right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection or subtotal colectomy) surgery. 3. patient has consented to be in the trial and signed informed consent is available before any study related procedures are carried out. exclusion criteria: 1. subject has gastroparesis. 2. subject has significant multisystem (autonomic) diseases. 3. subject has a body mass index greater than 35 kg/m2 4. subject has an autoimmune disorder requiring therapy in the preceding 2 years. 5. subject has significant cardiac arrhythmia or ectopy. 6. obstructing lesion and pre obstruction bowel dilatation 7. subject has an existing implanted electrical stimulator (e.g., pacemaker. 8. subject requires chronic anticoagulant therapy 9. subject is currently enrolled in other potentially confounding research. 10. pregnancy 11. current alcohol abuse 12. subject poses a significant general anesthesia risk 13. subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.

Keywords: exero anastomotic leak impedance ischemia colon bowel
evaluation of effectiveness and safety of the genous stent (iris-genous stemi)

Conditions: Coronary Artery Disease

Summary: the objective of this study is to evaluate effectiveness and safety of genous epc-coated stent in patients with stemi with other drug-eluting stents (dess).

this study is a non-randomized, prospective, open-label registry to compare the efficacy and safety of genous stent in stemi patients with other-type dess.

Eligibility criteria:
inclusion criteria: * stemi patients requiring primary pci. * the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethics committee of the respective clinical site exclusion criteria: * patients with a mixture of other dess * terminal illness with life expectancy \<1 year * patients with cardiogenic shock

Keywords: drug eluting stents
effect of salvia hispanica l. (chia) in the biochemical metabolic syndrome components

Conditions: Metabolic Syndrome X

Summary: the objective of this study is to evaluate the effect of the administration of 25 g of chia per day, for 90 days on the biochemical components of the metabolic syndrome in subjects with this condition

the metabolic syndrome (ms) is a cardiovascular risk factor and is present in about 20-25% of the world's adult population. individuals with this condition have twice the risk of cardiovascular disease and die from it, compared with those who do not and 5 times more likely to develop type 2 diabetes mellitus (dm2). for this reason, it is appropriate to develop better tools for prevention and management of ms, with more emphasis on lifestyle´s changes. chia has been studied in the past 10 years due to its high concentration of omega-3 alpha-linolenic acid (ala) and 6 linoleic acid (la) showing beneficial effects in some components of ms in rodents and individuals. the addition of chia to the conventional treatment of ms for the modification of metabolic disorders provides us a tool for easy incorporation into daily life, inexpensive and accessible in our environment.

Eligibility criteria:
inclusion criteria: * diagnosis of metabolic syndrome according to adult treatment panel - iii criteria. * subject wishing to participate in the study by written consent. * instituto mexicano del seguro social beneficiaries subject * subject who not requiring modification of medical treatment for ms in the recruitment period. exclusion criteria: * chronic renal failure with filtration glomerular rate clearance less than 30ml / min. * diabetic neuropathy. * post menopause * intestinal malabsorption diseases . * type 2 diabetes with hba1c \> 8.5 % * systolic and diastolic blood pressure \>140/90 mmhg. * triglycerides \> 300 mg/dl. * ldl cholesterol \>160mg/dl. * systemic autoimmune diseases . * cirrhosis or liver failure . * subject infected with human immunodeficiency virus or acquired immunodeficiency syndrome . * diagnosis of cancer with active disease. * subject previously undergoing bariatric surgery. * pregnancy or lactation. * alcoholism and drug addiction. * subject who consume high fiber dietary supplements and / or omega 3 acids. * subject taking anorexic drugs. * subject under diet for weight loss implemented by a health professional.

Keywords: metabolic syndrome x chia dyslipidemia
retinal endo vascular surgery for central retinal vein occlusion

Conditions: Central Retinal Vein Occlusion

Summary: patients with central retinal vein occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and tpa will be injected into the obstracted vein.

patients with central retinal vein occlusion less than 6 month duration and reduction of vision to 6/21 will go oct and fang examinations. patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rtpa 200mcg/ml will be injected to the vein.

Eligibility criteria:
inclusion criteria: * crvo less than 6 month * visual acuity less than 6/21 * no prior eye surgery except cataract. exclusion criteria: * retinal/iris neovascularization

Keywords: retinal vein occlusion rtpa
addition of homeopathy in patients with resistant arterial hypertension

Conditions: Hypertension, Resistant to Conventional Therapy

Summary: resistant hypertension (rhtn) is a common clinical problem faced by both primary care clinicians and specialists worldwide. patients with rhtn have higher rates of cardiovascular events and mortality compared with patients with more easily controlled hypertension. in addition, rhtn is often complicated by metabolic abnormalities. homeopathy, although widely used in hypertension, but no study has been taken to evaluate the impact on resistant hypertension. the aim of this trial was to evaluate individualized homeopathy on bp in patients with resistant hypertension.


Eligibility criteria:
inclusion criteria: * patients older than 18 years with resistant arterial hypertension. * office systolic bp \>140 mm hg or diastolic bp \>90 mm hg despite being treated with at least 3 antihypertensive drugs, including a diuretic. * patients with diabetes or chronic kidney disease (defined as serum creatinine \>133 μmol/l or proteinuria \>300 mg/day) if the office bp was \>130/80 mm hg. exclusion criteria: * severe hypertension (systolic bp \>180 mm hg or diastolic bp \>110 mm hg) who needed an immediate adjustment of treatment, * renal insufficiency with serum creatinine \>180 μmol/l or glomerular filtration rate \ 5.4 mmol/l, hyponatremia \<130 mmol/l, and porphyria; * pregnant or lactating women or women of fertile age not using effective contraception; * patients with known prior hypersensitivity to the drug verospiron (spironolactone; richter gedeon ltd) or who are currently using any aldosterone antagonist.

Keywords: resistant hypertension homeopathy blood pressure ambulatory blood pressure monitoring
intensity-modulated radiation therapy from 70gy to 80gy in localized prostate cancer

Conditions: Prostate Cancer

Summary: the objective is to report outcomes,including grade ≥2 overall late rectal and urinary toxicity and biochemical control rates in patients treated with imrt (70 gy, 74 gy and 80 gy)


Eligibility criteria:
inclusion criteria: consecutive patients from june 2000 to december 2010 with * untreated histologically confirmed adenocarcinoma of the prostate * stage t1c-t4 n0 m0 according to the 1992 american joint committee on cancer staging system exclusion criteria: * patients with positive pelvic lymphadenectomy or radiological positives nodes
an evaluation of the effect of community-based pharmacist intervention on patients with chronic pain

Conditions: Chronic Pain

Summary: this is a prospective, pre post, pilot cohort study to be conducted in patients with chronic pain, which is defined as pain that lasts beyond 3 months. to accomplish the primary and secondary objectives of the study, three phrases will be designed and completed during three months

this study will evaluate the effectiveness of community-based pharmacist interventions on the quality of life of patients with chronic pain as determined by self-reported pain levels using an established scoring system. participating pharmacists will enroll chronic pain patients from their normal practice to receive a consultation, which consists of an assessment of their current pain, a medication review, and education about their condition. based on the information provided by the patient, the pharmacist will prepare a care plan, contact the patient's prescriber, and, in conjunction with the prescriber, implement the plan to help relieve their pain. follow-up assessments will be done after 2 weeks, and 3 months.

Eligibility criteria:
inclusion criteria: 1. aged 18 or older 2. baseline average pain intensity using brief pain inventory is 6 or higher 3. ambulatory and able to attend the intervention 4. complaining of pain for 3 months or longer exclusion criteria: 1. patients with malignant or cancer pain 2. patients who are unable to communicate in english 3. non-ambulatory and unable to attend the intervention at the participating site 4. unable to give informed consent.
route registry of the utilisation of the transaortic (tao) tavi approach using the edwards sapien xt valve

Conditions: Aortic Stenosis

Summary: this is an international multi-center, prospective, observational registry with consecutive patient enrollment intended to determine outcome parameters within 30 days after transaortic transcatheter aortic valve replacement.

the purpose of this registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that are undergoing transaortic transcatheter procedure with the commercially available edwards sapien xt transcatheter heart valve with the ascendra+ system.

Eligibility criteria:
inclusion criteria: * intended transaortic (tao) tavi using edwards sapien xt transcatheter heart valve with the ascendra+ delivery-system * compliance with the indications according to the instructions for use * written informed consent exclusion criteria: * presence of contraindications as to the instructions for use * tao with concomitant procedure (e.g. tao + cabg) * participation in the source xt registry
erlotinib is being studied with or without an investigational drug, pf-02341066, in patients with lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with pf-02341066 in patients with advanced non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of non-small cell lung cancer (nsclc) that is locally advanced or metastatic and of the adenocarcinoma subtype (including mixed adenosquamous histology) * evident disease progression by response evaluation criterion in solid tumors (recist) after at least one but no more than 2 chemotherapy regimens for advanced disease * tumors must have measurable disease as per recist exclusion criteria: * known interstitial lung disease * prior treatment with an agent that is known or proposed to be active by action on egfr tyrosine kinase or c-met/hgf (phase 2 portion)

Keywords: lung neoplasms crizotinib
the impact of manual or mechanical ways to perform plr on the accuracy of evaluation of fluid responsiveness

Conditions: Circulatory Failure

Summary: our goal was to study the impact of different ways to perform passive leg raising (plr) on the accuracy of evaluation of fluid responsiveness.

patients who have shock of all kinds of reasons usually need to be transferred to the intensive care unit(icu) for monitoring and treatment due to unstable vital signs and high fatal risks. the cardiac function of these patients requires special attention. fluid responsiveness is a comprehensive reflection of preload and cardiac function, which provides guidance on how to conduct fluid replacement therapy. when patients have fluid responsiveness, it means that after fluid resuscitation therapy, the patients' cardiac output will increase and tissue perfusion will improve, bringing benefits to patients themselves. therefore, it is of vital significance to evaluate the presence of fluid responsiveness in patients before fluid therapy in clinical practice. passive leg raising(plr) is a commonly used method in clinical practice to evaluate patients' fluid responsiveness. but its accuracy is affected by the way the leg lifting is performed. this project is aimed to explore the impact of different ways to perform passive leg raising on the accuracy of evaluation of fluid responsiveness.

Eligibility criteria:
inclusion criteria: * (1) patients who have signs of tissue hypo-perfusion (increasing lactate levels, in need of vasopressor agents to maintain blood pressure, oliguria, and weak consciousness), and need to evaluate their fluid responsiveness; (2) patients who have received pulse indicator continuous cardiac output (picco) monitoring ; (3) patients who are transferred into the intensive care department. exclusion criteria: * (1) age \ 75 years old (2) pregnancy or lactation; (3) refusal to sign the informed consent form for enrollment; (4) patients who are clearly unable to perform passive leg raising (plr) (intra-abdominal pressure ≥16cmh2o, high risk of lower limb venous thrombosis, intracranial hypertension, and recent undergone abdominal or pelvic surgery); (5) patients with the contraindications of fluid resuscitation therapy ( pulmonary edema, intracranial hypertension and so on); (6) patients clinical doctors assessed as unsuitable for plr.

Keywords: fluid responsiveness passive leg raising
the postoperative head position as a predictor of the surgical outcome after dmek

Conditions: Fuchs Endothelial Corneal Dystrophy; Pseudophakic Bullous Keratopathy; Chemical Burn of Cornea; Posterior Polymorphous Corneal Dystrophy

Summary: this study aims to investigate the influence of postoperative head position on clinical outcomes after dmek via a wearable sensor.

after descemet membrane endothelial keratoplasty (dmek) patients are recommended to keep a strict supine position within the first few days after surgery in order to attach the graft to the corneal stroma. it has not yet been investigated to what extent the head position actually has an effect on the outcome. in this study, the participants head position will be continuously monitored within the first three days after dmek. participants wear a headband in which a small sensor is inserted. the degree of deviation from the neutral position will then be correlated with clinical outcomes.

Eligibility criteria:
inclusion criteria: * all patients undergoing dmek exclusion criteria: * no specific exclusion criteria

Keywords: descemet membrane endothelial keratoplasty dmek fuchs endothelial corneal dystrophy pseudophakic bullous keratopathy chemical burn of cornea posterior polymorphous corneal dystrophy postoperative head position corneal transplantation head tracking sensor
a post marketing survey study to evaluate the safety and effectiveness of prezista

Conditions: Acquired Immune Deficiency Syndrome

Summary: the purpose of this study is to assess the safety data of darunavir in a natural clinical practice.

this is a non-interventional (a scientific study to make a clear and easy understanding of the cause and effect relationship), prospective (in which the participants are first identified and then followed forward as time passes), consecutive survey for collecting safety and efficacy data of darunavir in treatment of acquired immune deficiency syndrome (aids) in a natural clinical practice.

Eligibility criteria:
inclusion criteria: * patients who are prescribed with darunavir for treatment of acquired immune deficiency syndrome (aids) exclusion criteria: * known hypersensitivity to prezista * prezista coadministered with medicinal products that are highly dependent on cyp3a for clearance

Keywords: acquired immune deficiency syndrome aids tmc114 darunavir prezista
lumbar erector spinae plane block vs fascia iliaca block vs lumbar plexus block for postoperative analgesia for total hip arthroplasty

Conditions: Lumbar Erector Spinae Plane Block; Fascia Iliaca Block; Lumbar Plexus Block; Analgesia; Total Hip Arthroplasty

Summary: this study aims to compare lumbar erector spinae plane block, fascia iliaca block, and lumbar plexus block for postoperative analgesia for hip surgery.

approximately 500,000 hip arthroplasties are performed each year in the united states. traditionally, this procedure has been performed under general anesthesia. however, neuraxial and regional anesthesia have become more commonly utilized to aid in postoperative analgesia and reduce the side effects of opioids, namely sedation, nausea, and vomiting. postoperative pain control has a significant impact on earlier ambulation, initiation of physical therapy, better functional recovery, and overall patient satisfaction. lumbar erector spinae plane block (lespb) was reported to lead to effective postoperative analgesia in hip and proximal femoral surgery. the fascia iliaca block (fib) is an established and effective technique, especially when us guidance and proximal approaches are used. lumbar plexus block (lpb) could be safe because of the targeted somatic nerve block in the psoas region which prevents dispensable sympathetic block even in cardiovascular-compromised patients.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * both sexes. * american society of anesthesiology (asa) physical status i-iii. * undergoing total hip arthroplasty under spinal anesthesia. exclusion criteria: * obesity (body mass index \> 30 kg/m2). * allergy to any drug used in the study. * contraindications to spinal anesthesia (such as thrombocytopenia (platelets \ 1.4 or insufficient time since stopping systemic anticoagulation)). * epilepsy. * psychiatric disease. * pre-existing neurologic deficits or neuropathies. * pregnancy. * pre-existing alcohol/opioid use disorder. * previously diagnosed with chronic pain.
evaluate the pharmacokinetics of oral arsenic trioxide solution under fasting and fed conditions, to compare intravenous arsenic trioxide, in acute promyelocytic leukemia

Conditions: Acute Promyelocytic Leukemia (APL)

Summary: randomized, open-label study to evaluate the pharmacokinetics of oral arsenic trioxide solution (sdk001) under fasting and fed conditions, to compare to iv arsenic trioxide


Eligibility criteria:
inclusion criteria: -diagnosis of apl characterized by the presence of the t(15;17) translocation or promyelocytic leukemia/retinoic acid receptor alpha gene expression exclusion criteria: * relapsed or refractory apl

Keywords: apl
biomarker changes in samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.

objectives: * map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations. * acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (aml). * investigate functional relationships between genetic and epigenetic landscapes in aml. outline: archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. genome-wide locations of 5 histone modifications are analyzed using chip-seq, as well as dna methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. these epigenetic data are correlated with genomic data (sequence analysis, expression array, snp array).

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia * primary leukemia samples from the children oncology group (cog) bank with sufficient number of cells (500,000-1 million cells) with \> 80% of leukemia blasts patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies